Inhaltsverzeichnis
Werbung
20. Beaudenon, S.; Kremsdorf, D.; Obalek, S.; Jablonska, S.; Pehau-Arnaudet, G.; Croissant, O.;
Orth, G. Plurality of genital human papillomaviruses: characterization of two new types with
distinct biological properties. Virology 161:374-384; 1987.
21. Lorincz, A. T.; Reid, R.; Jenson, A. B.; Greenberg, M. D.; Lancaster, W.; Kurman, R. J. Human
papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types.
Obstet Gynecol 79:328-337; 1992.
22. Koutsky, L. A.; Holmes, K. K.; Critchlow, C. W.; Stevens, C. E.; Paavonen, J.; Beckmann, A. M.;
DeRouen, T. A.; Galloway, D. A.; Vernon, D.; Kiviat, N. B. A cohort study of the risk of cervical
intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med
327:1272-1278; 1992.
23. Nieminen, P.; Aho, M.; Vesterinen, E.; Stellato, G.; Vaheri, A.; Soares, V. R. X.; Paavonen, J.
Natural history of HPV infection: preliminary results of a cohort study [abstract]. In: 1991
Papillomavirus Workshop. Seattle, WA: 1991: 77.
24. Sehulster, L. M.; Hollinger, F. B.; Dreesman, G. R.; Melnick, J. L. Immunological and biophysical
alteration of hepatitis B virus antigens by sodium hypochlorite disinfection. Appl Envir Microbiol
42(5):762-767; 1981.
25. Spire, B.; Barré-Sinoussi, F.; Montagnier, L.; Chermann, J. C. Inactivation of lymphadenopathy
associated virus by chemical disinfectants. Lancet; 1984 October 20: pp. 899-901.
26. Martin, L. S.; McDougal, J. S.; Loskoski, S. L. Disinfection and inactivation of the human T
lymphotropic virus type III/lymphadenopathy-associated virus. J Infect Dis 152(2):400-403; 1985.
27. Lorincz, A. T.; Schiffman, M. H.; Jaffurs, W. J.; Marlow, J.; Quinn, A. P.; Temple, G. F. Temporal
associations of human papillomavirus infection with cervical cytologic abnormalities. Am J Obstet
Gynecol 162(3):645-651; 1990.
28. Morrison, E. A. B.; Ho, G. Y. F.; Vermund, S. H.; Goldberg, G. L.; Kadish, A. S.; Kelley, K. F.;
Burk, R. D. Human papillomavirus infection and other risk factors for cervical neoplasia: a
case-control study. Int J Cancer 49:6-13; 1991.
29. Kahn, T.; Schwarz, E.; zur Hausen, H. Molecular cloning and characterization of the DNA of a
new human papillomavirus (HPV 30) from a laryngeal carcinoma. Int J Cancer 51:61-65; 1986.
30. Schiffman, M. Latest HPV findings: some clinical implications. Cont. OB/GYN 38(10):27-40; 1993.
31. Volpers, C.; Streeck, R. E. Genome organization and nucleotide sequence of human
papillomavirus type 39. Virology 181:419-423; 1991.
32. Matsukura, T.; Sugase, M. Molecular cloning of a novel human papillomavirus (type 58) from an
invasive cervical carcinoma. Virology 177:833-836; 1990.
33. Rho, J.; Roy-Burman, A.; Kim, H.; de Villiers, E.M.; Matsukura, T.; Choe, J. Nucleotide sequence
and phylogenetic classification of human papillomavirus type 59. Virology 203:158-161; 1994.
34. Longuet, M.; Beaudenon, S.; Orth, G. Two novel genital human papillomavirus (HPV) types,
HPV68 and HPV70, related to the potentially oncogenic HPV39. J Clin Microbiol 34(3):738-744;
1996.
35. Bosch, F.X.; Manos, M.M.; Munoz, N.; Sherman, M.; Jansen, A.M.; Peto, J.;Schiffman, M.H.;
Moreno,V.; Kurman,R.; Shah, K.V.; International Biological Study on Cervical Cancer (IBSCC)
Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.
JNCI 87(11):796-802; 1995.
36. Wheeler, C.M.; Stewart, A.M.; Gravitt, P.E.; Cheng, S. Generation of entire human papillomavirus
genomes by long PCR: frequency of errors produced during amplification. Genome Research
5(1):79-88; 1995.
37. RD Burke, P Kelly, J Feldman, et. al., Declining Prevalence of Cervicovaginal Human
Papillomavirus Infection With Age Is Independent of Other Risk Factors, Sexually Transmitted
Diseases, Juli-August, 1996:333-341).
38. Meyer, T., et. al., Association of Rare Human Papillomavirus Types with Genital Premalignant
and Malignant Lesions, J. Infectious Diseases, 178:252-255 (1998).
46
Werbung
Inhaltsverzeichnis
